Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIPE | Q05469 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.42 |
| ▸ | POLB | P06746 | 3/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | MMP1 | P03956 | 2/20 | 0.38 |
| ▸ | MMP2 | P08253 | 2/20 | 0.38 |
| ▸ | MMP3 | P08254 | 2/20 | 0.38 |
| ▸ | MMP9 | P14780 | 2/20 | 0.38 |
| ▸ | MMP8 | P22894 | 1/20 | 0.38 |
| ▸ | MMP13 | P45452 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17093002 | 0.87 | SMN1; SMN2 (0.46) | ALDH1A1POLBSMN1; SMN2LMNATHRB | |
| SCHEMBL19493323 | 0.84 | ALDH1A1 (0.42) | ALDH1A1POLBSMN1; SMN2LMNATHRB | |
| SCHEMBL15934092 | 0.82 | KDM4E (0.47) | ALDH1A1POLBSMN1; SMN2LMNATDP1 | |
| SCHEMBL11559149 | 0.82 | ALDH1A1 (0.43) | ALDH1A1POLBSMN1; SMN2TDP1THRB | |
| SCHEMBL1949240 | 0.82 | SMN1; SMN2 (0.51) | ALDH1A1POLBSMN1; SMN2LMNATDP1 | |
| SCHEMBL15139532 | 0.81 | ALDH1A1 (0.41) | ALDH1A1POLBLMNATHRBATM | |
| SCHEMBL14180427 | 0.81 | SMN1; SMN2 (0.65) | ALDH1A1POLBSMN1; SMN2LMNATDP1 | |
| SCHEMBL22115802 | 0.81 | ALDH1A1 (0.48) | ALDH1A1POLBSMN1; SMN2LMNATHRB | |
| SCHEMBL1713386 | 0.81 | SMN1; SMN2 (0.40) | ALDH1A1POLBSMN1; SMN2LMNATDP1 | |
| SCHEMBL3313940 | 0.81 | POLB (0.40) | ALDH1A1POLBSMN1; SMN2LMNATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111349185-B | Solid catalyst for propylene polymerization and method for producing block copolymer using the same | 韩华道达尔能源有限公司 | 2023-02-03 | — | — | CN | disclosed |
| US-11427657-B2 | Solid catalyst for propylene polymerization and method of producing block copolymer using the same | HANWHA TOTAL PETROCHEMICAL CO., LTD. (KR) | 2022-08-30 | — | — | US | disclosed |
| CN-111349185-A | Solid catalyst for propylene polymerization and method for producing block copolymer using the same | 韩华道达尔有限公司 | 2020-06-30 | — | — | CN | disclosed |
| US-20200199266-A1 | Solid Catalyst For Propylene Polymerization And Method Of Producing Block Copolymer Using The Same | HANWHA TOTALENERGIES PETROCHEMICAL CO., LTD. (KR) | 2020-06-25 | — | — | US | disclosed |
| EP-3670546-A1 | SOLID CATALYST FOR PROPYLENE POLYMERIZATION AND METHOD OF PRODUCING BLOCK COPOLYMER USING THE SAME | Hanwha Total Petrochemical Co., Ltd. (KR) | 2020-06-24 | — | — | EP | disclosed |
| CN-107847765-A | The piperidine derivative of 1,4 substitutions | 赛福伦公司 | 2018-03-27 | — | — | CN | disclosed |
| CN-102971311-B | Bicyclic heteroaryl compounds as GPR119 modulators | BRISTOL MYERS SQUIBB CO | 2015-07-08 | — | — | CN | disclosed |
| CN-102971311-A | Bicyclic heteroaryl compounds as GPR119 modulators | BRISTOL MYERS SQUIBB CO | 2013-03-13 | — | — | CN | disclosed |
| EP-2004157-A2 | USE OF GPR119 RECEPTOR AGONISTS FOR INCREASING BONE MASS AND FOR TREATING OSTEOPOROSIS, AS WELL AS COMBINATION THERAPY RELATING THERETO | Arena Pharmaceuticals, Inc. (US) | 2008-12-24 | — | — | EP | disclosed |
| WO-2007120702-A2 | USE OF GPR119 RECEPTOR AGONISTS FOR INCREASING BONE MASS AND FOR TREATING OSTEOPOROSIS, AND COMBINATION THERAPY RELATING THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2007-10-25 | — | — | WO | disclosed |
| EP-1758565-A2 | COMBINATION THERAPY FOR THE TREATMENT OF DIABETES AND CONDITIONS RELATED THERETO AND FOR THE TREATMENT OF CONDITIONS AMELIORATED BY INCREASING A BLOOD GLP-1 LEVEL | Arena Pharmaceuticals, Inc. (US) | 2007-03-07 | — | — | EP | disclosed |
| WO-2006076231-A2 | COMBINATION THERAPY FOR THE TREATMENT OF DIABETES AND CONDITIONS RELATED THERETO AND FOR THE TREATMENT OF CONDITIONS AMELIORATED BY INCREASING A BLOOD GLP-1 LEVEL | ARENA PHARMACEUTICALS, INC. (US) | 2006-07-20 | — | — | WO | disclosed |